EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group

L. Y. Dirix, F. Tonnesen, J. Cassidy, R. Epelbaum, W. W. Ten Bokkel Huinink, N. Pavlidis, R. Sorio, T. Gamucci, I. Wolff, A. Te Velde, J. Lan, J. Verweij

Research output: Contribution to journalArticlepeer-review

Abstract

In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.

Original languageEnglish
Pages (from-to)2019-2022
Number of pages4
JournalEuropean Journal of Cancer
Volume32
Issue number11
DOIs
Publication statusPublished - Oct 1996

Keywords

  • Breast cancer
  • Colorectal cancer
  • EO9
  • Gastric cancer
  • Pancreatic cancer
  • Phase II study
  • Proteinuria
  • Renal toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group'. Together they form a unique fingerprint.

Cite this